查看文章

Results: Thirty-nine patients were enrolled and treated with SABR between March 2019 and January 2022, all to a dose of 50 Gy in 5 fractions, at five institutions in Canada and 1 in Scotland. Median age was 78 years (interquartile range: 67-83), 59% were male, and 92% had a history of smoking (median 43 pack-years). At baseline, 70% reported dyspnea, median FEV1 was 80% predicted and median DLCO was 49% predicted. ILD-GAP scores were as follows:≤ 2 (ie best ILD status): n= 14; 3-5: n= 23;≥ 6 (ie worst ILD status): n= 2. Median follow-up was 19 months. OS at one-year was 78.9%(p< 0.001 by binomal test versus the unacceptable rate). Median OS was 25 months, median PFS was 19 months, and two-year LC was 92%. AE rates (possibly, probably or definitely related) were as follows (highest grade per patient): Grade 1-2: n= 12 (31%); Grade 3: n= 4 (10%); Grade 4; n= 0; Grade 5 n= 3 (7.7%, all due …